-
Columbia University v. Gen Digital: $185M Cybersecurity Patent Verdict Reopened and Trial Counsel Sanctions Vacated
A pair of related decisions issued by the Federal Circuit in Trustees of Columbia University v. Gen Digital Inc. , Nos. 24-1243, -1244 (Fed. Cir. Mar 11, 2026),…
4 min read
-
Implicit v. Sonos: Federal Circuit Holds That Post-IPR Inventorship Corrections Cannot Undo Forfeited Arguments
The Federal Circuit’s recent decision in Implicit, LLC v. Sonos, Inc., No. 25-853 (Fed. Cir. Mar. 9, 2026), addresses a procedural question that arises occasionally in patent litigation…
4 min read
-
Exafer v. Microsoft: Federal Circuit Rejects Per Se Rule Against Using Unaccused Products in Patent Royalty Base
The Federal Circuit’s decision in Exafer Ltd. v. Microsoft Corp., No. 24-2296 (Fed. Cir. Mar 6, 2026), addresses a recurring and often misunderstood issue in patent damages law:…
4 min read
-
Magnolia v. Kurin: Separately Listed Claim Elements Require Separate Structures
The Federal Circuit’s decision in Magnolia Medical Technologies, Inc. v. Kurin, Inc., No. 2024-2001 (Fed. Cir. Mar. 6, 2026) reinforces a claim construction principle that appears simple but has…
4 min read
-
Global Tubing v. Tenaris: “Smoking Gun” Isn’t Enough for Summary Judgment on Inequitable Conduct or Walker Process Fraud
The Federal Circuit’s decision in Global Tubing LLC v. Tenaris Coiled Tubes LLC, No. 2023-1882 (Fed. Cir. Feb. 26, 2026) delivers a sharp reminder that even apparently damning…
4 min read
-
REGENXBIO v. Sarepta Therapeutics: Recombinant AAV Host Cells Are Not Products of Nature
On February 20, 2026, the Federal Circuit issued a significant decision clarifying the scope of patent eligibility for genetically engineered compositions in REGENXBIO Inc. v. Sarepta Therapeutics, Inc.,…
4 min read
